A compound of Formula I: ##STR00001##
wherein Y is O, S, or Se;
wherein each X.sup.1-X.sup.14 is independently C or N;
wherein two consecutive X.sup.1-X.sup.14 in the same ring are not N;
wherein any of X.sup.1-X.sup.14 is C when it forms a direct bond to R.sup.A, R.sup.B, R.sup.C, or R.sup.D;
wherein R.sup.A, R.sup.B, R.sup.C, and R.sup.D each independently represent mono to the maximum allowable substitution, or no substitution;
wherein each R.sup.A, R.sup.B, R.sup.C, and R.sup.D is independently a hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof;
wherein R.sup.D represents mono to the maximum allowable substitution at least one R.sup.D is not hydrogen; and
wherein any two substituents are optionally joined or fused together to form a ring.

The present invention relates to certain 4-substituted 1H-pyrrolo[2,3-b]pyridine compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds is useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of ErbB receptor, especially of Exon20 Her2 and EGFR mutations.

##STR00001##

Disclosed herein are novel carborane hydroxamic acid matrix metalloproteinase (“MMP”) inhibitors and agents bearing borane-containing moieties and methods for their use in treating or preventing a disease, such as cancer and rheumatoid arthritis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: Formula (I) wherein the substituents are as described. ##STR00001##

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

The present disclosure relates to a compound represented by Formula 1 and an organic light emitting device using the same. The compound used as a material of an organic material layer of the organic light emitting device provides improved efficiency, low driving voltage, and improved lifetime characteristic.

Provided is a plasma enhanced atomic layer deposition (PEALD) process for depositing etch-resistant SiOCN films. These films provide improved growth rate, improved step coverage and excellent etch resistance to wet etchants and post-deposition plasma treatments containing O.sub.2 and NH.sub.3 co-reactants. This PEALD process relies on one or more precursors reacting in tandem with the plasma exposure to deposit the etch-resistant thin-films of SiOCN. The films display excellent resistance to wet etching with dilute aqueous HF solutions, both after deposition and after post-deposition plasma treatment(s). Accordingly, these films are expected to display excellent stability towards post-deposition fabrication steps utilized during device manufacturing and build.

The present invention relates to an organic electroluminescent device comprising a light-emitting layer B containing at least one host compound H of Formula (I)

##STR00001##

wherein each of X′.sub.1 and X′.sub.2 is independently from another selected from the group consisting of nitrogen and an optionally substituted carbon atom, and wherein at least one of R′.sub.1-R′.sub.10 is CN and at least one of R.sub.A-R.sub.E is a substituted silane residue.

A compound for an organic optoelectronic device, a composition for an organic optoelectronic device including the same, an organic optoelectronic device, and a display device, the compound being represented by Chemical Formula 1:

##STR00001##

A light-emitting that includes a first electrode, a second electrode on the first electrode, and at least one functional layer between the first electrode and the second electrode is provided. At least one functional layer may include an aromatic compound represented by Formula 1. The light-emitting element results in a reduced driving voltage and an improved luminous efficiency.

##STR00001##

Disclosed is a polycyclic compound that can be employed in various organic layers of an organic electroluminescent device. Also disclosed is an organic electroluminescent device including the polycyclic compound. The organic electroluminescent device includes a light emitting layer employing the polycyclic compound as a dopant and an anthracene derivative having a characteristic structure and characteristic substituents as a host. The use of the polycyclic compound significantly improves the color purity, luminous efficiency, and life characteristics of the organic electroluminescent device and makes the organic electroluminescent device highly efficient and long lasting.